|
| [通信作者]史俊,Email：shijun8700@126.com |
| Effects of argatroban on neurological function and vascular reactivity in patients with mild atherosclerotic ischemic stroke |
| 投稿时间：2024-09-08 修订日期：2025-01-24 |
| DOI： |
| 中文关键词: 阿加曲班;轻型卒中;大动脉粥样硬化性卒中;经颅多普勒超声 |
| 英文关键词: Argatroban;Mild stroke;Large artery atherosclerotic stroke;Transcranial Doppler ultrasound |
| 基金项目:]常州市科技计划项目(CJ20209001) |
| 作者 | 单位 | 邮编 | | 史俊* | 溧阳市人民医院 | 213300 | | 张虚琴 | 溧阳市人民医院 | | | 缪莲莲 | 溧阳市人民医院 | | | 黄红伟 | 溧阳市人民医院 | |
|
| 摘要点击次数: 11 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探讨阿加曲班对轻型大动脉粥样硬化性缺血性卒中(LAAS)患者神经功能和血管反应性的影响。方法 纳入2021年6月至2023年6月入院的急性轻型LAAS患者160例,分为阿加曲班组(n=80)和对照组(n=80)。分别在治疗前、治疗7d后对患者进行美国国立卫生院卒中量表(NIHSS)、改良Rankin量表(mRS)、简明精神状态量表(MMSE)的评估和经颅多普勒超声(TCD)屏气试验,对结果进行比较分析。结果 (1)2组患者的一般临床资料差异无统计学意义(P＞0.05)。在治疗7d后,对照组出现27例(33.8%)进展性卒中,明显高于阿加曲班组的12例(15%),差异有统计学意义(c2=0.629,P=0.006)。(2)在治疗7d后,阿加曲班组的NIHSS评分[2.0(1.0,3.0)分]低于对照组[3.0(1.0,6.0)](P=0.017),mRS量表评级为0~2的患者[67例(83.8%)]多于对照组[56例(70.0%)](P=0.039)；(3)在治疗7d后,阿加曲班组的MMSE评分[(24.96±3.37)分]明显高于对照组[(22.67±4.01)分](P=0.000)和治疗前[(22.12±3.35)分](P=0.000)。(4)阿加曲班组在治疗7d后的屏气后平均血流速度及屏气指数(BHI)明显高于对照组(P＜0.05)。阿加曲班组治疗7d后的屏气前、后平均血流速度及BHI较治疗前明显升高(P＜0.05)。结论 阿加曲班可以改善急性轻型LAAS患者的脑血流调节能力,减少进展性卒中的发生,改善患者的肢体功能和认知功能。 |
| 英文摘要: |
| Objective To explore the effect of agatroban on neurological function and vascular reactivity in patients with mild atherosclerotic ischemic stroke (LAAS). Methods 160 patients with acute mild LAAS admitted from June 2021 to June 2023 were divided into an agatroban group and a control group, with 80 patients in each group. Patients were evaluated using the National Institutes of Health Stroke Scale (NIHSS), Modified Rankin Scale (mRS), Mini Mental State Scale (MMSE), and Transcranial Doppler Ultrasound (TCD) breath holding test before treatment and 7 days after treatment. The results were compared and analyzed. Results (1)There was no significant difference in general clinical data between the two groups of patients (P>0.05). After 7 days of treatment, the control group experienced 27 cases (33.8%) of progressive stroke, which was significantly higher than that of agatroban group(12 cases(15%)), and the difference was statistically significant(c2=0.629,P=0.006).(2)After 7 days of treatment, the NIHSS score of agatroban(2.0(1.0,3.0))was lower than that of the control group(3.0(1.0,6.0)) (P=0.017). There were more patients in the agatran group(67cases(83.8%)) with mRS scale ratings of 0-2 than that in the control group(56cases(70.0%)) (P=0.039).(3)After 7 days of treatment, the MMSE score of agatroban (24.96 ± 3.37)was significantly higher than that of the control group (22.67 ± 4.01) (P=0.000) and before treatment (22.12 ± 3.35) (P=0.000).(4)The average blood flow velocity and breath holding index (BHI) of agatroban group after 7 days of treatment were significantly higher than those of the control group (P<0.05). The average blood flow velocity and BHI before and after 7 days of treatment of agatroban group were significantly higher than before treatment (P<0.05). Conclusion Agatroban can improve the cerebral blood flow regulation ability of patients with acute mild LAAS, reduce the occurrence of progressive stroke, and improve their limb and cognitive functions. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
|
|
|
